Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study
Journal of the American Academy of Dermatology · 2026-06 · 94 (6) · 1826-1827
DOI: 10.1016/j.jaad.2026.02.042 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of the American Academy of Dermatology, 2026-06. Verfasst von Henry O Herrera und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Case Western Reserve University, Cleveland, Ohio. Electronic address: hoh2@case.edu. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The widespread use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for type 2 diabetes and obesity has prompted investigation into their dermatologic side effects, including hair loss.1 Prior studies have associated semaglutide and tirzepatide with potential hair loss.2-4 This retrospective population-based cohort study used TriNetX, a multicenter database of de-identified electronic medical records, to evaluate whether patients treated with semaglutide and tirzepatide developed new-onset hair loss.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Case Western Reserve University, Cleveland, Ohio. Electronic address: hoh2@case.edu.
- Department of Dermatology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio.
Zitieren
APA
Herrera, H. O., & Bordeaux, J. S. (2026). Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study. Journal of the American Academy of Dermatology, 94(6), 1826-1827. https://doi.org/10.1016/j.jaad.2026.02.042
Vancouver
Herrera HO, Bordeaux JS. Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study. Journal of the American Academy of Dermatology. 2026;94(6):1826-1827. doi:10.1016/j.jaad.2026.02.042
BibTeX
@article{Herrera2026,
author = {Herrera, Henry O and Bordeaux, Jeremy S},
title = {Risk of new-onset hair loss with semaglutide and tirzepatide: A TriNetX cohort study},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
volume = {94},
number = {6},
pages = {1826--1827},
doi = {10.1016/j.jaad.2026.02.042}
}
EUVIMED